BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/3/2022 8:55:07 AM | Browse: 412 | Download: 1338
 |
Received |
|
2022-01-28 11:16 |
 |
Peer-Review Started |
|
2022-01-28 11:18 |
 |
First Decision by Editorial Office Director |
|
2022-04-10 20:32 |
 |
Return for Revision |
|
2022-04-10 20:32 |
 |
Revised |
|
2022-05-20 08:36 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2022-07-11 02:52 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2022-07-11 16:06 |
 |
Articles in Press |
|
2022-07-11 16:06 |
 |
Edit the Manuscript by Language Editor |
|
2022-07-03 21:38 |
 |
Typeset the Manuscript |
|
2022-07-25 02:52 |
 |
Publish the Manuscript Online |
|
2022-08-03 07:54 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Control Study |
| Article Title |
Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Juliane Malik, Martin Klammer, Vinzent Rolny, Henry Lik-Yuen Chan, Teerha Piratvisuth, Tawesak Tanwandee, Satawat Thongsawat, Wattana Sukeepaisarnjaroen, Juan Ignacio Esteban, Marta Bes, Bruno Köhler and Magdalena Swiatek-de Lange |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Juliane Malik, PhD, N/A, N/A, N/A, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany. juliane.malik@roche.com |
| Key Words |
Carcinoma; Hepatocellular; MicroRNAs; Biomarkers; Alpha-fetoprotein; Protein induced by vitamin K absence-II; Diagnosis |
| Core Tip |
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and has a high mortality rate, making early diagnosis essential for better treatment outcomes. Studies have shown microRNAs to be early markers for HCC; we evaluated the potential diagnostic role of microRNAs alone and in combination with known protein biomarkers (alpha-fetoprotein, protein induced by vitamin K absence/antagonist-II) in samples from HCC-affected individuals and controls using real-time quantitative PCR and next-generation sequencing. MiR-21 and miR-423 demonstrated significant differential expression between the HCC and control groups. MicroRNAs alone or as a signature in combination with protein biomarkers did not improve diagnostic performance of the protein biomarkers. |
| Publish Date |
2022-08-03 07:54 |
| Citation |
Malik J, Klammer M, Rolny V, Chan HLY, Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, Swiatek-de Lange M. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. World J Gastroenterol 2022; 28(29): 3917-3933 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i29/3917.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i29.3917 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.